Leap Therapeutics Inc (LPTX)

1.1700
-0.0400(-3.31%)
After Hours
1.1600
-0.0100(-0.8547%)
- Real-time Data
  • Volume:
    538,930
  • Day's Range:
    1.1000 - 1.2300
  • 52 wk Range:
    0.9200 - 4.1700

LPTX Overview

Prev. Close
1.21
Day's Range
1.1-1.23
Revenue
1.14M
Open
1.21
52 wk Range
0.92-4.17
EPS
-0.55
Volume
538,930
Market Cap
103.33M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
760,619
P/E Ratio
-
Beta
0.75
1-Year Change
-27.78%
Shares Outstanding
88,318,454
Next Earnings Date
Aug 12, 2022
What is your sentiment on Leap Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Leap Therapeutics Inc News

Leap Therapeutics Inc Analysis

Leap Therapeutics Inc Company Profile

Leap Therapeutics Inc Company Profile

Employees
36

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellSellStrong Sell
SummaryStrong BuyBuyStrong SellStrong SellStrong Sell
  • hi
    0
    • https://twitter.com/gastriccancerfd/status/1227642373620015104?s=21
      0